<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37598239</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders.</ArticleTitle><Pagination><StartPage>13524</StartPage><MedlinePgn>13524</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13524</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-39805-z</ELocationID><Abstract><AbstractText>The NLRP3 inflammasome is an intracellular, multiprotein complex that promotes the auto-catalytic activation of caspase-1 and the subsequent maturation and secretion of the pro-inflammatory cytokines, IL-1&#x3b2; and IL-18. Persistent activation of the NLRP3 inflammasome has been implicated in the pathophysiology of a number of inflammatory and autoimmune diseases, including neuroinflammation, cardiovascular disease, non-alcoholic steatohepatitis, lupus nephritis and severe asthma. Here we describe the preclinical profile of JT002, a novel small molecule inhibitor of the NLRP3 inflammasome. JT002 potently reduced NLRP3-dependent proinflammatory cytokine production across a number of cellular assays and prevented pyroptosis, an inflammatory form of cell death triggered by active caspase-1. JT002 demonstrated in vivo target engagement at therapeutically relevant concentrations when orally dosed in mice and prevented body weight loss and improved inflammatory and fibrotic endpoints in a model of Muckle-Wells syndrome (MWS). In two distinct models of neutrophilic airway inflammation, JT002 treatment significantly reduced airway hyperresponsiveness and airway neutrophilia. These results provide a rationale for the therapeutic targeting of the NLRP3 inflammasome in severe asthma and point to the use of JT002 in a variety of inflammatory disorders.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ambrus-Aikelin</LastName><ForeName>Geza</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Katsuyuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Jewish Health, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joetham</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Jewish Health, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazic</LastName><ForeName>Milos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povero</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA. povero.davide@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. povero.davide@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santini</LastName><ForeName>Angelina M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pranadinata</LastName><ForeName>Rama</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Casey D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGeough</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beasley</LastName><ForeName>Federico C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stansfield</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trzoss</LastName><ForeName>Lynnie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Hal M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldstein</LastName><ForeName>Ariel E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stafford</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veal</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bain</LastName><ForeName>Gretchen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Jecure Therapeutics, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelfand</LastName><ForeName>Erwin W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Jewish Health, Denver, CO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>G.A.-A., M.L., D.P., A.S., R.P., F.C.B., R.S., C.M., L.T., J.A.S., J.M.V., and G.B. were employees of Jecure Therapeutics when this work was performed. G.A.-A., M.L., D.P., A.S., R.P., R.S., C.M., L.T., A.E.F., J.A.S., J.M.V., and G.B. were shareholders of Jecure Therapeutics when this work was performed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>19</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37598239</ArticleId><ArticleId IdType="pmc">PMC10439952</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-39805-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-39805-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821&#x2013;832. doi: 10.1016/j.cell.2010.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.040</ArticleId><ArticleId IdType="pubmed">20303873</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, Callaway JB, Ting JP. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat. Med. 2015;21:677&#x2013;687. doi: 10.1038/nm.3893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3893</ArticleId><ArticleId IdType="pmc">PMC4519035</ArticleId><ArticleId IdType="pubmed">26121197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013&#x2013;1022. doi: 10.1016/j.cell.2014.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.04.007</ArticleId><ArticleId IdType="pubmed">24855941</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Lieberman J. Advances in Immunology. Academic Press; 2017. pp. 81&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10245508</ArticleId><ArticleId IdType="pubmed">28826530</ArticleId></ArticleIdList></Reference><Reference><Citation>England H, Summersgill HR, Edye ME, Rothwell NJ, Brough D. Release of interleukin-1alpha or interleukin-1beta depends on mechanism of cell death. J. Biol. Chem. 2014;289:15942&#x2013;15950. doi: 10.1074/jbc.M114.557561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.557561</ArticleId><ArticleId IdType="pmc">PMC4047367</ArticleId><ArticleId IdType="pubmed">24790078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutterwala FS, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity. 2006;24:317&#x2013;327. doi: 10.1016/j.immuni.2006.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.02.004</ArticleId><ArticleId IdType="pubmed">16546100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayagaki N, et al. Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479:117&#x2013;121. doi: 10.1038/nature10558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10558</ArticleId><ArticleId IdType="pubmed">22002608</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 2016;41:1012&#x2013;1021. doi: 10.1016/j.tibs.2016.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5123939</ArticleId><ArticleId IdType="pubmed">27669650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayagaki N, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526:666&#x2013;671. doi: 10.1038/nature15541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15541</ArticleId><ArticleId IdType="pubmed">26375259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidt MM, et al. Human monocytes engage an alternative inflammasome pathway. Immunity. 2016;44:833&#x2013;846. doi: 10.1016/j.immuni.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.01.012</ArticleId><ArticleId IdType="pubmed">27037191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman HM, Broderick L. The role of the inflammasome in patients with autoinflammatory diseases. J. Allergy Clin. Immunol. 2016;138:3&#x2013;14. doi: 10.1016/j.jaci.2016.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.05.001</ArticleId><ArticleId IdType="pubmed">27373321</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksentijevich I, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46:3340&#x2013;3348. doi: 10.1002/art.10688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10688</ArticleId><ArticleId IdType="pmc">PMC4556432</ArticleId><ArticleId IdType="pubmed">12483741</ArticleId></ArticleIdList></Reference><Reference><Citation>Brydges SD, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30:875&#x2013;887. doi: 10.1016/j.immuni.2009.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.05.005</ArticleId><ArticleId IdType="pmc">PMC2759865</ArticleId><ArticleId IdType="pubmed">19501000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle&#x2013;Wells syndrome. Nat. Genet. 2001;29:301&#x2013;305. doi: 10.1038/ng756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng756</ArticleId><ArticleId IdType="pmc">PMC4322000</ArticleId><ArticleId IdType="pubmed">11687797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangan MSJ, et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 2018;17:588&#x2013;606. doi: 10.1038/nrd.2018.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.97</ArticleId><ArticleId IdType="pubmed">30026524</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Walle L, et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature. 2014;512:69&#x2013;73. doi: 10.1038/nature13322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13322</ArticleId><ArticleId IdType="pmc">PMC4126806</ArticleId><ArticleId IdType="pubmed">25043000</ArticleId></ArticleIdList></Reference><Reference><Citation>Paramel GV, Sirsjo A, Fransen K. Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease. Mediat. Inflamm. 2015;2015:846782. doi: 10.1155/2015/846782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/846782</ArticleId><ArticleId IdType="pmc">PMC4348606</ArticleId><ArticleId IdType="pubmed">25788762</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Bae SC. Association between functional NLRP3 polymorphisms and susceptibility to autoimmune and inflammatory diseases: A meta-analysis. Lupus. 2016;25:1558&#x2013;1566. doi: 10.1177/0961203316644336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316644336</ArticleId><ArticleId IdType="pubmed">27060062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R, et al. Podocyte Activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 2017;69:1636&#x2013;1646. doi: 10.1002/art.40155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40155</ArticleId><ArticleId IdType="pmc">PMC5568813</ArticleId><ArticleId IdType="pubmed">28544564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu A, et al. Hyperactivation of the NLRP3 inflammasome in myeloid cells leads to severe organ damage in experimental lupus. J. Immunol. 2017;198:1119&#x2013;1129. doi: 10.4049/jimmunol.1600659.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600659</ArticleId><ArticleId IdType="pubmed">28039299</ArticleId></ArticleIdList></Reference><Reference><Citation>Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. Nat. Rev. Rheumatol. 2018;14:341&#x2013;353. doi: 10.1038/s41584-018-0004-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0004-x</ArticleId><ArticleId IdType="pubmed">29740155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mridha AR, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 2017;66:1037&#x2013;1046. doi: 10.1016/j.jhep.2017.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2017.01.022</ArticleId><ArticleId IdType="pmc">PMC6536116</ArticleId><ArticleId IdType="pubmed">28167322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wree A, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. (Berl.) 2014;92:1069&#x2013;1082. doi: 10.1007/s00109-014-1170-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-014-1170-1</ArticleId><ArticleId IdType="pmc">PMC4349416</ArticleId><ArticleId IdType="pubmed">24861026</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasetti Fantauzzi C, et al. Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic steatohepatitis induced by high-fat diet: Possible role of the NLRP3 inflammasome. Oxid. Med. Cell Longev. 2017;2017:8962458. doi: 10.1155/2017/8962458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8962458</ArticleId><ArticleId IdType="pmc">PMC5705892</ArticleId><ArticleId IdType="pubmed">29270247</ArticleId></ArticleIdList></Reference><Reference><Citation>Wree A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898&#x2013;910. doi: 10.1002/hep.26592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26592</ArticleId><ArticleId IdType="pmc">PMC4008151</ArticleId><ArticleId IdType="pubmed">23813842</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey C, et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav. Immun. 2017;61:306&#x2013;316. doi: 10.1016/j.bbi.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.12.014</ArticleId><ArticleId IdType="pubmed">28003153</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra S, et al. NLRP3 inflammasome is associated with the response to IFN-beta in patients with multiple sclerosis. Brain. 2015;138:644&#x2013;652. doi: 10.1093/brain/awu388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu388</ArticleId><ArticleId IdType="pmc">PMC4408432</ArticleId><ArticleId IdType="pubmed">25586466</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll RC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015;21:248&#x2013;255. doi: 10.1038/nm.3806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3806</ArticleId><ArticleId IdType="pmc">PMC4392179</ArticleId><ArticleId IdType="pubmed">25686105</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie BA, et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2018 doi: 10.1073/pnas.1722041115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1722041115</ArticleId><ArticleId IdType="pmc">PMC6042136</ArticleId><ArticleId IdType="pubmed">29895691</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan R, et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 1999;163:2403&#x2013;2409. doi: 10.4049/jimmunol.163.5.2403.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.163.5.2403</ArticleId><ArticleId IdType="pubmed">10452974</ArticleId></ArticleIdList></Reference><Reference><Citation>Gris D, et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010;185:974&#x2013;981. doi: 10.4049/jimmunol.0904145.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0904145</ArticleId><ArticleId IdType="pmc">PMC3593010</ArticleId><ArticleId IdType="pubmed">20574004</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw PJ, et al. Cutting edge: Critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2010;184:4610&#x2013;4614. doi: 10.4049/jimmunol.1000217.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000217</ArticleId><ArticleId IdType="pmc">PMC3001131</ArticleId><ArticleId IdType="pubmed">20368281</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hout GP, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur. Heart J. 2017;38:828&#x2013;836. doi: 10.1093/eurheartj/ehw247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw247</ArticleId><ArticleId IdType="pubmed">27432019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandanger O, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 2013;99:164&#x2013;174. doi: 10.1093/cvr/cvt091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvt091</ArticleId><ArticleId IdType="pubmed">23580606</ArticleId></ArticleIdList></Reference><Reference><Citation>Primiano MJ, et al. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J. Immunol. 2016;197:2421&#x2013;2433. doi: 10.4049/jimmunol.1600035.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600035</ArticleId><ArticleId IdType="pubmed">27521339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim RY, et al. Role for NLRP3 inflammasome-mediated, IL-1beta-dependent responses in severe, steroid-resistant asthma. Am. J. Respir. Crit. Care Med. 2017;196:283&#x2013;297. doi: 10.1164/rccm.201609-1830OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201609-1830OC</ArticleId><ArticleId IdType="pubmed">28252317</ArticleId></ArticleIdList></Reference><Reference><Citation>Riteau N, et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 2010;182:774&#x2013;783. doi: 10.1164/rccm.201003-0359OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201003-0359OC</ArticleId><ArticleId IdType="pubmed">20522787</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin. Exp. Immunol. 2018;194:231&#x2013;243. doi: 10.1111/cei.13167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13167</ArticleId><ArticleId IdType="pmc">PMC6194337</ArticleId><ArticleId IdType="pubmed">30277570</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera AP, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci. Rep. 2018;8:8618. doi: 10.1038/s41598-018-26775-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-26775-w</ArticleId><ArticleId IdType="pmc">PMC5988655</ArticleId><ArticleId IdType="pubmed">29872077</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson JL, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur. Respir. J. 2014;43:1067&#x2013;1076. doi: 10.1183/09031936.00105013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00105013</ArticleId><ArticleId IdType="pubmed">24136334</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossios C, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. J. Allergy Clin. Immunol. 2018;141:560&#x2013;570. doi: 10.1016/j.jaci.2017.02.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.02.045</ArticleId><ArticleId IdType="pubmed">28528200</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F, Mayor A, Tschopp J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 2009;27:229&#x2013;265. doi: 10.1146/annurev.immunol.021908.132715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132715</ArticleId><ArticleId IdType="pubmed">19302040</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucher D, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J. Exp. Med. 2018;215:827&#x2013;840. doi: 10.1084/jem.20172222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20172222</ArticleId><ArticleId IdType="pmc">PMC5839769</ArticleId><ArticleId IdType="pubmed">29432122</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanthakumar CB, et al. Dissecting fibrosis: Therapeutic insights from the small-molecule toolbox. Nat. Rev. Drug Discov. 2015;14:693&#x2013;720. doi: 10.1038/nrd4592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4592</ArticleId><ArticleId IdType="pubmed">26338155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ii M, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 2006;69:1288&#x2013;1295. doi: 10.1124/mol.105.019695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.105.019695</ArticleId><ArticleId IdType="pubmed">16373689</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinstein L, et al. An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes. Clin. Immunol. 2018;191:100&#x2013;109. doi: 10.1016/j.clim.2017.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.11.011</ArticleId><ArticleId IdType="pubmed">29183866</ArticleId></ArticleIdList></Reference><Reference><Citation>Joetham A, et al. Inducible and naturally occurring regulatory T cells enhance lung allergic responses through divergent transcriptional pathways. J. Allergy Clin. Immunol. 2017;139:1331&#x2013;1342. doi: 10.1016/j.jaci.2016.06.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.06.051</ArticleId><ArticleId IdType="pmc">PMC5313386</ArticleId><ArticleId IdType="pubmed">27542981</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara S, et al. Vgamma1+ T cells and tumor necrosis factor-alpha in ozone-induced airway hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 2009;40:454&#x2013;463. doi: 10.1165/rcmb.2008-0346OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2008-0346OC</ArticleId><ArticleId IdType="pmc">PMC2660562</ArticleId><ArticleId IdType="pubmed">18927346</ArticleId></ArticleIdList></Reference><Reference><Citation>Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat. Rev. Rheumatol. 2016;12:14&#x2013;24. doi: 10.1038/nrrheum.2016.166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.166</ArticleId><ArticleId IdType="pubmed">26656658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017;377:1119&#x2013;1131. doi: 10.1056/NEJMoa1707914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707914</ArticleId><ArticleId IdType="pubmed">28845751</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F, et al. Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays. Toxicol. Sci. 2015;147:500&#x2013;514. doi: 10.1093/toxsci/kfv152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfv152</ArticleId><ArticleId IdType="pubmed">26206150</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388&#x2013;396. doi: 10.1002/hep.26208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26208</ArticleId><ArticleId IdType="pubmed">23258593</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson LA. Electrophilic intermediates produced by bioactivation of furan. Drug Metab. Rev. 2006;38:615&#x2013;626. doi: 10.1080/03602530600959417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03602530600959417</ArticleId><ArticleId IdType="pubmed">17145691</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride C, et al. Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A potent and selective NLRP3 inhibitor. J. Med. Chem. 2022;65:14721&#x2013;14739. doi: 10.1021/acs.jmedchem.2c01250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01250</ArticleId><ArticleId IdType="pubmed">36279149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>